{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:28:16Z","timestamp":1791412096391,"version":"4.3.3"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:00:00Z","timestamp":1608854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To report the findings of the 2019 Society for Hematopathology\/European Association for Haematopathology Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and myeloid and lymphoid neoplasms associated with eosinophilia (excluding entities covered by other studies in this series).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The workshop panel reviewed 109 cases, assigned consensus diagnosis, and created diagnosis-specific sessions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24). Myeloproliferative neoplasms (MPNs) received 17 submissions, including chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Myelodysplastic syndrome (MDS), MDS\/MPN, and therapy-related myeloid neoplasms received 11, while GDE and HES received 12 and 11 submissions, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypereosinophilia and HES are defined by specific clinical and laboratory criteria. Eosinophilia is commonly reactive. An acute leukemic onset with eosinophilia may suggest core-binding factor acute myeloid leukemia, blast phase of chronic myeloid leukemia, BCR-ABL1\u2013positive leukemia, or t(5;14) B-lymphoblastic leukemia. Eosinophilia is rare in MDS but common in MDS\/MPN. CEL, NOS is a clinically aggressive MPN with eosinophilia as the dominant feature. Bone marrow morphology and cytogenetic and\/or molecular clonality may distinguish CEL from HES. Molecular testing helps to better subclassify myeloid neoplasms with eosinophilia and to identify patients for targeted treatments.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa244","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T04:22:45Z","timestamp":1603945365000},"page":"179-210","source":"Crossref","is-referenced-by-count":31,"title":["Eosinophilia\/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders"],"prefix":"10.1093","volume":"155","author":[{"given":"Katalin","family":"Kelemen","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Saft","sequence":"additional","affiliation":[{"name":"Department of Pathology, Karolinska University Hospital and Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E","family":"Craig","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Texas Tech University Health Sciences Center, El Paso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-7663","authenticated-orcid":false,"given":"Megan","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B","family":"Wertheim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Munich (LMU), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, Eberhard Karls University of T\u00fcbingen and Comprehensive Cancer Center, T\u00fcbingen University Hospital, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K","family":"Reichard","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,25]]},"reference":[{"key":"2021020409563062700_CIT0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijlh.12955","article-title":"How I investigate eosinophilia","volume":"41","author":"Larsen","year":"2019","journal-title":"Int J Lab Hematol."},{"key":"2021020409563062700_CIT0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol."},{"key":"2021020409563062700_CIT0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000489341","article-title":"The diagnostic work-up of hypereosinophilia","volume":"86","author":"Wang","year":"2019","journal-title":"Pathobiology."},{"key":"2021020409563062700_CIT0004","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood."},{"key":"2021020409563062700_CIT0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"2021020409563062700_CIT0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2009.01.001","article-title":"Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders","volume":"23","author":"Valent","year":"2009","journal-title":"Blood Rev."},{"key":"2021020409563062700_CIT0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"2021020409563062700_CIT0008","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia."},{"key":"2021020409563062700_CIT0009","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM199003293221301","article-title":"Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan","volume":"322","author":"Hertzman","year":"1990","journal-title":"N Engl J Med."},{"key":"2021020409563062700_CIT0010","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18:1243","author":"Cho","year":"2017","journal-title":"Int J Mol Sci."},{"key":"2021020409563062700_CIT0011","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S0031182016000834","article-title":"Human infection with Strongyloides stercoralis and other related Strongyloides species","volume":"144","author":"Nutman","year":"2017","journal-title":"Parasitology."},{"key":"2021020409563062700_CIT0012","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.iac.2015.05.001","article-title":"Eosinophilia in rheumatologic\/vascular disorders","volume":"35","author":"Tamaki","year":"2015","journal-title":"Immunol Allergy Clin North Am."},{"key":"2021020409563062700_CIT0013","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017"},{"key":"2021020409563062700_CIT0014","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol."},{"key":"2021020409563062700_CIT0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia."},{"key":"2021020409563062700_CIT0016","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Rajala","year":"2013","journal-title":"Blood."},{"key":"2021020409563062700_CIT0017","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.3324\/haematol.2014.104992","article-title":"The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse","volume":"99","author":"Bandapalli","year":"2014","journal-title":"Haematologica."},{"key":"2021020409563062700_CIT0018","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood."},{"key":"2021020409563062700_CIT0019","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat Commun."},{"key":"2021020409563062700_CIT0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2016-09-737817","article-title":"Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea","volume":"129","author":"Ma","year":"2017","journal-title":"Blood."},{"key":"2021020409563062700_CIT0021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica."},{"key":"2021020409563062700_CIT0022","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood."},{"key":"2021020409563062700_CIT0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol."},{"key":"2021020409563062700_CIT0024","first-page":"330","article-title":"A myelodysplastic syndrome with marrow eosinophilia terminating in acute nonlymphocytic leukemia, associated with an abnormal chromosome 16","volume":"111","author":"Abbondanzo","year":"1987","journal-title":"Arch Pathol Lab Med."},{"key":"2021020409563062700_CIT0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2362.2008.01950.x","article-title":"Mixed-lineage eosinophil\/basophil crisis in MDS: a rare form of progression","volume":"38","author":"Wimazal","year":"2008","journal-title":"Eur J Clin Invest."},{"key":"2021020409563062700_CIT0026","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2141.1993.tb03139.x","article-title":"Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group","volume":"84","author":"Matsushima","year":"1993","journal-title":"Br J Haematol."},{"key":"2021020409563062700_CIT0027","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2002-03-0947","article-title":"Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia","volume":"101","author":"Matsushima","year":"2003","journal-title":"Blood."},{"key":"2021020409563062700_CIT0028","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5045\/br.2013.48.3.222","article-title":"A case of myelodysplastic syndrome with marked eosinophilia showing favorable prognosis","volume":"48","author":"Kim","year":"2013","journal-title":"Blood Res."},{"key":"2021020409563062700_CIT0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000039744","article-title":"Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration","volume":"104","author":"Kuroda","year":"2000","journal-title":"Acta Haematol."},{"key":"2021020409563062700_CIT0030","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.3389\/fimmu.2018.03031","article-title":"Severe eosinophilia in myelodysplastic syndrome with a defined and rare cytogenetic abnormality","volume":"9","author":"Rai","year":"2018","journal-title":"Front Immunol."},{"key":"2021020409563062700_CIT0031","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol."},{"key":"2021020409563062700_CIT0032","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.3324\/haematol.2019.230193","article-title":"Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (&lt;10%) or with other types of disease progression","volume":"105","author":"Geyer","year":"2020","journal-title":"Haematologica."},{"key":"2021020409563062700_CIT0033","first-page":"181","article-title":"P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia","volume":"29","author":"G\u00fcran","year":"1998","journal-title":"Haematologia (Budap)."},{"key":"2021020409563062700_CIT0034","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia."},{"key":"2021020409563062700_CIT0035","first-page":"130","article-title":"Acute myeloid leukemia with recurrent genetic abnormalities","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Arber","year":"2017"},{"key":"2021020409563062700_CIT0036","first-page":"150","article-title":"Acute myeloid leukemia with myelodysplasia related changes","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Arber","year":"2017"},{"key":"2021020409563062700_CIT0037","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-05-1064","article-title":"Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation","volume":"11","author":"Sperr","year":"2005","journal-title":"Clin Cancer Res."},{"key":"2021020409563062700_CIT0038","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/bloodadvances.2018016675","article-title":"Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation","volume":"2","author":"Xiao","year":"2018","journal-title":"Blood Adv."},{"key":"2021020409563062700_CIT0039","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V73.8.2081.2081","article-title":"The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene","volume":"73","author":"Grimaldi","year":"1989","journal-title":"Blood."},{"key":"2021020409563062700_CIT0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1532\/LH96.07018","article-title":"Acute lymphoblastic leukemia with hypereosinophilia and 9p21 deletion: case report and review of the literature","volume":"14","author":"D\u2019Angelo","year":"2008","journal-title":"Lab Hematol."},{"key":"2021020409563062700_CIT0041","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5858\/arpa.2011-0597-RA","article-title":"Diagnostic complexities of eosinophilia","volume":"137","author":"Montgomery","year":"2013","journal-title":"Arch Pathol Lab Med."},{"key":"2021020409563062700_CIT0042","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaip.2016.03.020","article-title":"Hypereosinophilia in children and adults: a retrospective comparison","volume":"4","author":"Williams","year":"2016","journal-title":"J Allergy Clin Immunol Pract."},{"key":"2021020409563062700_CIT0043","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3389\/fimmu.2018.01944","article-title":"An approach to the evaluation of persistent hypereosinophilia in pediatric patients","volume":"9","author":"Schwartz","year":"2018","journal-title":"Front Immunol."},{"key":"2021020409563062700_CIT0044","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-016-0130-4","article-title":"Primary immunodeficiencies associated with eosinophilia","volume":"12","author":"Navabi","year":"2016","journal-title":"Allergy Asthma Clin Immunol."},{"key":"2021020409563062700_CIT0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10875-017-0453-z","article-title":"Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome","volume":"38","author":"Candotti","year":"2018","journal-title":"J Clin Immunol."},{"key":"2021020409563062700_CIT0046","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/imcb.12209","article-title":"Hyper IgE syndromes: clinical and molecular characteristics","volume":"97","author":"Al-Shaikhly","year":"2019","journal-title":"Immunol Cell Biol."},{"key":"2021020409563062700_CIT0047","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1172\/JCI114368","article-title":"Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome","volume":"84","author":"Del Prete","year":"1989","journal-title":"J Clin Invest."},{"key":"2021020409563062700_CIT0048","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-immunol-051116-052350","article-title":"Th2 cells in health and disease","volume":"35","author":"Nakayama","year":"2017","journal-title":"Annu Rev Immunol."},{"key":"2021020409563062700_CIT0049","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.141.7.2335","article-title":"IL-4 is required to generate and sustain in vivo IgE responses","volume":"141","author":"Finkelman","year":"1988","journal-title":"J Immunol."},{"key":"2021020409563062700_CIT0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2 innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature."},{"key":"2021020409563062700_CIT0051","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med."},{"key":"2021020409563062700_CIT0052","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3389\/fimmu.2018.01080","article-title":"STAT3-mediated transcriptional regulation of osteopontin in STAT3 loss-of-function related hyper IgE syndrome","volume":"9","author":"Goel","year":"2018","journal-title":"Front Immunol."},{"key":"2021020409563062700_CIT0053","doi-asserted-by":"crossref","first-page":"535-","DOI":"10.1016\/j.immuni.2007.05.007","article-title":"The hyper IgE syndrome and mutations in TYK2","volume":"26","author":"Woellner","year":"2007","journal-title":"Immunity."},{"key":"2021020409563062700_CIT0054","article-title":"A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity","volume":"3:eaat4956","author":"Beziat","year":"2018","journal-title":"Sci Immunol."},{"key":"2021020409563062700_CIT0055","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1056\/NEJMoa0905506","article-title":"Combined immunodeficiency associated with DOCK8 mutations","volume":"361","author":"Zhang","year":"2009","journal-title":"N Engl J Med."},{"key":"2021020409563062700_CIT0056","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1172\/JCI85774","article-title":"A DOCK8-WIP-WASp complex links T cell receptors to the actin cytoskeleton","volume":"126","author":"Janssen","year":"2016","journal-title":"J Clin Invest."},{"key":"2021020409563062700_CIT0057","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/imm.12945","article-title":"Differential T-cell receptor signals for T helper cell programming","volume":"155","author":"Morel","year":"2018","journal-title":"Immunology."},{"key":"2021020409563062700_CIT0058","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archdermatol.2011.262","article-title":"Cutaneous manifestations of DOCK8 deficiency syndrome","volume":"148","author":"Chu","year":"2012","journal-title":"Arch Dermatol."},{"key":"2021020409563062700_CIT0059","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fped.2019.00451","article-title":"Wiskott-Aldrich syndrome (WAS) and dedicator of cytokinesis 8- (DOCK8) deficiency","volume":"7","author":"Albert","year":"2019","journal-title":"Front Pediatr."},{"key":"2021020409563062700_CIT0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/nyas.12049","article-title":"Wiskott-Aldrich syndrome: a comprehensive review","volume":"1285","author":"Massaad","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"2021020409563062700_CIT0061","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2005-03-1219","article-title":"Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment","volume":"108","author":"Sabri","year":"2006","journal-title":"Blood."},{"key":"2021020409563062700_CIT0062","article-title":"Visual servoing-based nanorobotic system for automated electrical characterization of nanotubes inside SEM","volume":"18:1137","author":"Ding","year":"2018","journal-title":"Sensors (Basel)."},{"key":"2021020409563062700_CIT0063","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjh.15831","article-title":"How I manage patients with Wiskott Aldrich syndrome","volume":"185","author":"Rivers","year":"2019","journal-title":"Br J Haematol."},{"key":"2021020409563062700_CIT0064","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaci.2018.04.017","article-title":"Screening for Wiskott-Aldrich syndrome by flow cytometry","volume":"142","author":"Chiang","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"2021020409563062700_CIT0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fimmu.2018.00203","article-title":"Novel CARMIL2 mutations in patients with variable clinical dermatitis, infections, and combined immunodeficiency","volume":"9","author":"Alazami","year":"2018","journal-title":"Front Immunol."},{"key":"2021020409563062700_CIT0066","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1091\/mbc.E15-08-0552","article-title":"CARMIL2 is a novel molecular connection between vimentin and actin essential for cell migration and invadopodia formation","volume":"26","author":"Lanier","year":"2015","journal-title":"Mol Biol Cell."},{"key":"2021020409563062700_CIT0067","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.1038\/ncomms14209","article-title":"A human immunodeficiency syndrome caused by mutations in CARMIL2","volume":"8","author":"Schober","year":"2017","journal-title":"Nat Commun."},{"key":"2021020409563062700_CIT0068","doi-asserted-by":"crossref","first-page":"151413","DOI":"10.1016\/j.anndiagpath.2019.151413","article-title":"Peripheral eosinophilia in primary immunodeficiencies of actin dysregulation: a case series of Wiskott-Aldrich syndrome, CARMIL2 and DOCK8 deficiency and review of the literature","volume":"43","author":"Kim","year":"2019","journal-title":"Ann Diagn Pathol."},{"key":"2021020409563062700_CIT0069","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fimmu.2018.00369","article-title":"Activated PI3 kinase delta syndrome: from genetics to therapy","volume":"9","author":"Michalovich","year":"2018","journal-title":"Front Immunol."},{"key":"2021020409563062700_CIT0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaci.2019.01.033","article-title":"Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells","volume":"144","author":"Bier","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"2021020409563062700_CIT0071","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12887-019-1556-x","article-title":"Functional characteristics of circulating granulocytes in severe congenital neutropenia caused by ELANE mutations","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Pediatr."},{"key":"2021020409563062700_CIT0072","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminhematol.2006.04.004","article-title":"Severe congenital neutropenia","volume":"43","author":"Welte","year":"2006","journal-title":"Semin Hematol."},{"key":"2021020409563062700_CIT0073","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.molcel.2007.07.024","article-title":"A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation","volume":"27","author":"Zhu","year":"2007","journal-title":"Mol Cell."},{"key":"2021020409563062700_CIT0074","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood-2013-03-489641","article-title":"The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation","volume":"122","author":"Wang","year":"2013","journal-title":"Blood."},{"key":"2021020409563062700_CIT0075","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jaci.2016.10.053","article-title":"Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: genotoxic stress-associated bone marrow failure and developmental aberrations","volume":"140","author":"Bahrami","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"2021020409563062700_CIT0076","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaci.2015.06.008","article-title":"An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation","volume":"136","author":"Le Guen","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"2021020409563062700_CIT0077","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood-2013-09-527127","article-title":"MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts","volume":"122","author":"Alsultan","year":"2013","journal-title":"Blood."},{"key":"2021020409563062700_CIT0078","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","article-title":"Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients","volume":"103","author":"Donadieu","year":"2018","journal-title":"Haematologica."},{"key":"2021020409563062700_CIT0079","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood."},{"key":"2021020409563062700_CIT0080","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood."},{"key":"2021020409563062700_CIT0081","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1080\/10428194.2019.1630619","article-title":"Myelodysplastic\/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni syndrome","volume":"60","author":"Turner","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"2021020409563062700_CIT0082","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergencyto.2009.03.001","article-title":"Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition","volume":"192","author":"Bug","year":"2009","journal-title":"Cancer Genet Cytogenet."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/155\/2\/179\/36186756\/aqaa244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/155\/2\/179\/36186756\/aqaa244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:19:09Z","timestamp":1696972749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/155\/2\/179\/6046532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,25]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,25]]},"published-print":{"date-parts":[[2021,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa244","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,12,25]]}}}